The study enrolled 40 healthy women over 35 years of age: 32 reported symptoms associated with the menopause transition and eight reported no or minimal symptoms. All received 250 mg nicotinamide riboside and 50 mg pterostilbene for seven days.

The authors report favourable changes in selected self-reported symptoms and urinary metabolites related to vitamin B3 and oestrogens. The exploratory design primarily generates hypotheses about oestrogen recycling and NAD+ metabolism.

For R&D, the next step matters more than the initial signal: a randomised placebo-controlled trial, a duration suited to the objective, prespecified clinical endpoints, standardised hormone measurements and safety analysis.

The work does not prove that the combination provides durable improvement in menopause, does not isolate the contribution of either component and does not automatically support claims across the women’s-health category.

Why it matters

For women’s health, the case shows how a biological rationale must progress to prespecified endpoints, controls, adequate duration and independent replication before supporting product positioning.

Evidence limit

Open-label study lasting seven days, with 40 participants and a commercial product. It does not establish durable clinical benefit or separate the effects of NR and pterostilbene.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Frontiers in Aging ↗